These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17650444)

  • 1. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
    Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
    Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
    Rambaldi A; Carlotti E; Oldani E; Della Starza I; Baccarani M; Cortelazzo S; Lauria F; Arcaini L; Morra E; Pulsoni A; Rigacci L; Rupolo M; Zaja F; Zinzani PL; Barbui T; Foa R
    Blood; 2005 May; 105(9):3428-33. PubMed ID: 15637137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
    Galimberti S; Palumbo GA; Caracciolo F; Benedetti E; Pelosini M; Brizzi S; Ciabatti E; Fazzi R; Stelitano C; Quintana G; Conte E; Tibullo D; Di Raimondo F; Petrini M
    J Chemother; 2007 Jun; 19(3):315-21. PubMed ID: 17594928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
    Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
    Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
    Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
    Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
    Ahlgrimm M; Pfreundschuh M; Kreuz M; Regitz E; Preuss KD; Bittenbring J
    Blood; 2011 Oct; 118(17):4657-62. PubMed ID: 21900198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
    Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
    Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
    van Oers MH; Van Glabbeke M; Giurgea L; Klasa R; Marcus RE; Wolf M; Kimby E; van t Veer M; Vranovsky A; Holte H; Hagenbeek A
    J Clin Oncol; 2010 Jun; 28(17):2853-8. PubMed ID: 20439641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N; Kodama F; Oshima R; Hashimoto C; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Sakai R; Fujita H; Fujisawa S; Kanamori H; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2006 Jun; 47(6):1041-7. PubMed ID: 16840195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
    Rambaldi A; Lazzari M; Manzoni C; Carlotti E; Arcaini L; Baccarani M; Barbui T; Bernasconi C; Dastoli G; Fuga G; Gamba E; Gargantini L; Gattei V; Lauria F; Lazzarino M; Mandelli F; Morra E; Pulsoni A; Ribersani M; Rossi-Ferrini PL; Rupolo M; Tura S; Zagonel V; Zaja F; Zinzani P; Reato G; Foa R
    Blood; 2002 Feb; 99(3):856-62. PubMed ID: 11806987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
    Büyükkurt N; Özcan MA; Ergene Ü; Payzın B; Tunalı S; Demirkan F; Özsan H; Pişkin Ö; Ündar B
    Turk J Haematol; 2015 Jun; 32(2):152-7. PubMed ID: 26316483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High molecular response rate and clinical correlation in patients with follicular lymphoma treated with cyclophosphamide-vincristine-prednisone plus interferon alpha 2b.
    Fernández-Ruiz E; Cabrerizo M; Ortega M; Blas C; Llamas P; Santos-Roncero M; Nieto S; Acevedo A; Pérez G; Nicolás C; Fernández-Rañada JM; Arranz R
    Clin Cancer Res; 2003 Jul; 9(7):2497-503. PubMed ID: 12855623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.
    Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S
    Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
    J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
    Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
    Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.
    Prochazka V; Papajik T; Gazdova J; Divoka M; Rozmanova S; Faber E; Raida L; Kucerova L; Langova K; Jarosova M; Indrak K
    Neoplasma; 2011; 58(3):263-70. PubMed ID: 21395368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.